MedTrace Logo

Topical Psoriasis Study for Patients Receiving Biologic Therapy

NCT02983981 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-03-20

Study results available
· View outcomes & findings →

Summary

A two-phase, single center, study of 20 subjects to assess 4 weeks of add-on therapy of Topicort® BID and 12 weeks BID on two consecutive days a week to patients with ≤5% BSA who are receiving biologic therapy for at least 24 weeks

Conditions

Interventions

DRUG

Topicort Topical Spray

open label Topicort spray

Sponsors & Collaborators

  • Sun Pharmaceutical Industries, Inc.

    collaborator INDUSTRY

  • Psoriasis Treatment Center of Central New Jersey

    lead OTHER

Principal Investigators

  • Jerry Bagel, MD · Director

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2016-09-30
Completion
2016-10-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02983981 on ClinicalTrials.gov